Ridgecrest Wealth Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
EP
Ridgecrest Wealth Partners's ARKG Position: Q4 2021 in Review
Ridgecrest Wealth Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 3,000 shares — an estimated $224K sold.
Ridgecrest Wealth Partners first reported a position in ARKG in Q1 2021 and held it in 3 quarters. The position peaked at $278K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.
- Ridgecrest Wealth Partners reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
- Ridgecrest Wealth Partners sold 3,000 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $224K.
- Ridgecrest Wealth Partners first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 3 quarters.
- Ridgecrest Wealth Partners's ARK Genomic Revolution ETF position peaked at $278K in Q2 2021.
- 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.
Based on Ridgecrest Wealth Partners's 13F filing for Q4 2021, filed 19 Jan 2022.